Investors with an eye on the biotechnology sector may find Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) an intriguing prospect. With a robust market capitalization of $6.17 billion and a focus on rare and orphan diseases, Mirum is carving out a niche in the healthcare industry. The company, headquartered in Foster City, California, is dedicated to developing and commercializing innovative therapies, with its lead product, LIVMARLI (maralixibat), gaining traction in the treatment of Alagille syndrome.

### Price and Valuation Metrics

Mirum’s stock is currently trading at $103.1, nearing the high end of its 52-week range of $38.39 to $105.45. The stock has experienced a slight price change of 0.01%, indicative of its current…